Long-Acting Etonogestrel Microsphere Injectable
DARE-204, DARE-214
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Phase I
- Developer(s)/researcher(s): Daré , Adare Pharma Solutions, Orbis
Details
- API: Etonogestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 1 Injection/6 or 12 Months
- MPT: Not Potential MPT
- Promising Attributes: Extended release ENG microspheres may have a steadier hormone dose and more rapid return to fertility than other injectables, and would fill a market gap for longer-acting injectables.
Product Status
Active Pre-Clinical Research
History
Precision Particle Fabrication technology for uniform microspheres originally developed by Orbis Biosciences, aquired by Adare Pharma Solutions in 2020.
2022: Daré announces NICHD funding to conduct user research regarding their pre-clinical ENG microsphere injectable concept, developed in collaboration with Adare Pharma Solutions.
As of 2025, Daré's product pipeline indicates that they are actively preparing to initiate a Phase I trial for Dare 204/214.